Prevalence of metabolic syndrome and its association with lower urinary tract symptoms and sexual function

Plata, Mauricio; Caicedo, Juan Ignacio; Trujillo, Carlos Gustavo; Mariño-Alvarez, Á.M.; Fernández, Nicolás; Gutierrez, A.; Godoy, F.; Cabrera, Mayela; Cataño, Juan Guillermo; Robledo, Daniela

doi:10.1016/j.acuroe.2017.07.006

Cited by 4 publications

(4 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Contrary to current reports, some studies conflicting results that MeTS was not associated with an increased risk of ED. In one of them, the authors stated no difference in the prevalence of ED between men with or without MetS but age, presence of depressive symptoms and lower education were significant predictors of ED 29 . Plata et al also reported no relationship between MetS and ED among urological patients, probably as a result of the low prevalence of MetS 29 .…”

Section: Discussionmentioning

confidence: 99%

“…In one of them, the authors stated no difference in the prevalence of ED between men with or without MetS but age, presence of depressive symptoms and lower education were significant predictors of ED 29 . Plata et al also reported no relationship between MetS and ED among urological patients, probably as a result of the low prevalence of MetS 29 . The methodological settings of these studies caused by the low number of MeTS patients might have been insufficient to explain the relationship between MeTS and ED.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Impact of high visceral adiposity index associated with metabolic syndrome on erectile function in sexually active men: Results of a cross‐sectional study

et al. 2021

View full text Add to dashboard Cite

Aims Erectile dysfunction (ED) is a common condition affected by many factors. We aimed to show the impact of the metabolic syndrome (MeTS) on male sexual function based on visceral adiposity index (VAI). Methods Participants who met MeTS criteria (Group 1, n = 96) and did not meet MeTS criteria (Group 2, n = 189) were included in this cross‐sectional study. The MeTS diagnosis was made in the presence of at least 3 of the following criteria: fasting serum glucose level higher than 100 mg/dL, HDL cholesterol level below 40 mg/dL, triglyceride level higher than 150 mg/dL, waist circumference higher than 102 cm and blood pressure higher than 130/85 mmHg. Demographic data were recorded; biochemical and hormonal tests were measured. Erectile and other sexual function scores were recorded. The VAI was calculated using the [(Waist Circumference/39.68) + (1.88 × body mass index)] × triglyceride/1.03 × 1.31/HDL formula. Results Mean age, smoking volume, testosterone (T) and testosterone/estradiol (T/E2) ratios of the groups were similar (P > .05). The mean VAI was two‐fold higher in patients in Group 1 (P < .001) and erectile function score was lower in Group 1 than Group 2 (P = .001). Other sexual function scores were similar (P > .05). The METS was associated with an increased risk of ED (P = .001). Logistic regression analysis showed that each integer increase in the VAI was associated with a 1.4‐fold increased risk of ED (P < .001). Higher T values were associated with a better erectile function (P = .03). For the VAI = 4.33, receiver‐operating characteristic analysis showed a sensitivity of 89.6% and specificity of 57.7%. Conclusion Compared with non‐MeTS, the presence of MeTS has emerged as a risk factor for patients with ED with high VAI levels while the other sexual functions are preserved. Management of ED patients with MeTS should cover a comprehensive metabolic and endocrinological evaluation in addition to andrological work up.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Impact of high visceral adiposity index associated with metabolic syndrome on erectile function in sexually active men: Results of a cross‐sectional study

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Even though PV is associated with LUTS, some studies did not collect data concerning PV. 66,67,83 Most studies defined general obesity as BMI ⩾30 kg/m 2 , while some studies included overweight participants (BMI = 25–29 kg/m 2 ). According to WHO (1999), BMI ⩾25 kg/m 2 indicates overweight and BMI ⩾30 kg/m 2 indicates obesity.…”

Section: Discussionmentioning

confidence: 99%

Metabolic syndrome is associated with prostate enlargement: a systematic review, meta-analysis, and meta-regression on patients with lower urinary tract symptom factors

Omran

Leca

Oštarijaš

et al. 2021

Therapeutic Advances in Endocrinology

View full text Add to dashboard Cite

Background: Metabolic syndrome (MetS) is defined by at least three of the following five criteria: blood pressure ⩾130/85 mmHg, fasting blood glucose ⩾5.6 mmol/l, triglycerides concentration ⩾1.7 mmol/l, waist circumference ⩾102 cm (for men), and high-density lipoprotein cholesterol concentration <1.03 mmol/l (for men). MetS has been associated with worse lower urinary tract symptoms (LUTS) and higher International Prostate Symptom questionnaire scores. Materials and Methods: MEDLINE, Cochrane, ClinicalTrials.gov, and SCOPUS were critically appraised for all peer-reviewed manuscripts that suitably fulfilled our protocol’s inclusion criteria established a priori. Meta-analytical and meta-regression calculations were performed in R using the Sidik–Jonkman and Hartung–Knapp random effects model and predefined covariates. Results: A total of 70 studies ( n = 90,206) were included in qualitative synthesis. From these, 60 studies focused on MetS and LUTS: 44 reported positive correlations, 5 reported negative correlations, 11 reported no association, and 10 studies focused on MetS and total prostate volume (TPV). MetS positively correlated with moderate LUTS [odds ratio (OR) = 1.56, 95% confidence interval (CI) = 1.35–1.80], severe LUTS (OR = 2.35, 95% CI = 1.82–3.03), overactive bladder (OAB; OR = 3.2, 95% CI = 1.6–5.8), and nocturia severity (OR = 2.509, 95% CI = 1.571–4.007) at multivariate analysis. A total of 30 studies ( n = 22,206) were included in meta-analysis; MetS was significantly associated with higher TPV (mean differences = 4.4450 ml, 95% CI = 2.0177–6.8723), but no significant predictive factors for effect sizes were discovered. Conclusion: Our meta-analysis demonstrates a significant association between the aggravating effects of MetS, which commonly coexists with obesity and benign prostate enlargement.

show abstract

“…It is estimated that 133 million Americans (or 45% of the population) suffer from at least one chronic disease, and this number is continuously increasing (11). LUTS were found to be highly prevalent in the aging population (12)(13)(14)(15)(16), and patients with chronic diseases and conditions such as obesity (17)(18)(19)(20)(21), metabolic syndrome (MetS) (22)(23)(24)(25)(26), diabetes (27)(28)(29)(30)(31), cardiovascular disease (32)(33)(34)(35)(36), hypertension (37)(38)(39), obstructive sleep apnea (OSA) (40)(41)(42)(43)(44)(45)(46), autoimmune diseases (47-50), Alzheimer's disease (51)(52)(53), and Parkinson's disease (54)(55)(56)(57). These diseases seem to adversely affect one or more organs in the lower urinary tract (bladder and urethra) and prostate, leading to LUTS.…”

Section: Introductionmentioning

confidence: 99%

Oxidative Stress: A Putative Link Between Lower Urinary Tract Symptoms and Aging and Major Chronic Diseases

Elrashidy

et al. 2022

Front. Med.

View full text Add to dashboard Cite

Aging and major chronic diseases are risk factors for lower urinary tract symptoms (LUTS). On the other hand, oxidative stress (OS) is one of the fundamental mechanisms of aging and the development of chronic diseases. Therefore, OS might be a candidate mechanism linking these two clinical entities. This article aims to summarize the studies on the prevalence of LUTS, the role of OS in aging and chronic diseases, and the potential mechanisms supporting the putative link. A comprehensive literature search was performed to identify recent reports investigating LUTS and OS in major chronic diseases. In addition, studies on the impact of OS on the lower urinary tract, including bladder, urethra, and prostate, were collected and summarized. Many studies showed LUTS are prevalent in aging and major chronic diseases, including obesity, metabolic syndrome, diabetes, cardiovascular disease, hypertension, obstructive sleep apnea, autoimmune diseases, Alzheimer’s disease, and Parkinson’s disease. At the same time, OS is a key component in the pathogenesis of those chronic diseases and conditions. Recent studies also provided evidence that exacerbated OS can cause functional and/or structural changes in the bladder, urethra, and prostate, leading to LUTS. The reviewed data support the concept that OS is involved in multiple risk factors-associated LUTS, although further studies are needed to confirm the causative relationship. The specific ROS/RNS and corresponding reactions/pathways involved in chronic diseases and associated LUTS should be identified in the future and could serve as therapeutic targets.

show abstract

Prevalence of metabolic syndrome and its association with lower urinary tract symptoms and sexual function

Cited by 4 publications

References 31 publications

Impact of high visceral adiposity index associated with metabolic syndrome on erectile function in sexually active men: Results of a cross‐sectional study

Impact of high visceral adiposity index associated with metabolic syndrome on erectile function in sexually active men: Results of a cross‐sectional study

Metabolic syndrome is associated with prostate enlargement: a systematic review, meta-analysis, and meta-regression on patients with lower urinary tract symptom factors

Oxidative Stress: A Putative Link Between Lower Urinary Tract Symptoms and Aging and Major Chronic Diseases

Contact Info

Product

Resources

About